OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasia Designed to resist competition from endogenous ACTH by maximizing receptor residency time OMS1620 demonstrates best-in-class efficacy in acute and chronic preclinical models of ACTH excess Oxford, United Kingdom – 14th July 2025 – OMass Therapeutics (‘OMass’ or ‘the […]
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules